Similar trends were observed for LOX-1 and CD36, where the P3 treatment led to a marked reduction in expression compared with the atherosclerosis control group (K+) and the other groups, indicating an inhibition of oxidized LDL uptake and foam cell formation. The gene discussed is CD36; the disease is atherosclerosis.